[MRTX] Mirati Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 110.7 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 5.35 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart MRTX

Refresh chart

Strongest Trends Summary For MRTX

MRTX is in the medium-term up 65% in 8 months. In the long-term up 1270% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Mirati Therapeutics, Inc., a biopharmaceutical company, is engaged in the development and commercialization of therapeutics for cancer and fungal diseases. Its lead product candidates include MGCD265, a multi-targeted kinase inhibitor that is in Phase I/II clinical trials for the treatment of solid tumors indications, including liver, renal cell, gastric, head and neck, prostate, pancreatic, bladder, breast, hepatocellular, ovarian, and non-small cell lung cancers; and MGCD516, a kinase inhibitor that is in advanced preclinical development stage for the treatment of patients with non-small cell lung cancer and solid tumors. The company also evaluates development opportunities for mocetinostat, a spectrum-selective histone deacetylase (HDAC) inhibitor for the treatment of patients with myelodysplastic syndrome and lymphoma. In addition, it develops MG96077, a beta-lactamase inhibitor; and MGCD290 for antifungal indications. The company has license, and research and development collaboration agreement with Taih

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding19.91 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV1.66 Price/Cash Per Share1.63
Price/Free Cash Flow-3.35 ROA-58.16% ROE-62.61% ROI
Current Ratio13.93 Quick Ratio Long Term Debt/Equity Debt Ratio0.08
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities48.61 M Cash From Operating Activities-31.12 M Gross Profit
Net Profit-9.78 M Operating Profit-11.99 M Total Assets72.18 M Total Current Assets71.19 M
Total Current Liabilities5.11 M Total Debt Total Liabilities5.13 M Total Revenue
Technical Data
High 52 week76.01 Low 52 week26.05 Last close75.99 Last change-0.03%
RSI82.18 Average true range3.24 Beta1.56 Volume82.99 K
Simple moving average 20 days8.28% Simple moving average 50 days30.83% Simple moving average 200 days51.82%
Performance Data
Performance Week4.64% Performance Month16.41% Performance Quart84% Performance Half30.45%
Performance Year168.04% Performance Year-to-date79.14% Volatility daily2.5% Volatility weekly5.59%
Volatility monthly11.45% Volatility yearly39.68% Relative Volume200.6% Average Volume635.6 K
New High New Low

News

2019-06-25 08:30:00 | Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock

2019-06-24 16:01:00 | Mirati Therapeutics Announces Proposed Public Offering of Common Stock

2019-06-24 09:43:00 | Read This Before You Buy Any New Cancer Drug Stocks

2019-06-17 13:30:00 | Shares of cancer-therapy companies skyrocket after Pfizer acquisition news

2019-06-14 08:41:12 | Implied Volatility Surging for Mirati Therapeutics MRTX Stock Options

2019-06-13 11:51:52 | 3 Under-the-Radar Stocks Trading at All-Time Highs

2019-06-12 10:03:52 | Mirati Therapeutics, Inc. NASDAQ:MRTX: Financial Strength Analysis

2019-06-10 10:26:30 | Hedge Funds Have Never Been This Bullish On Mirati Therapeutics, Inc. MRTX

2019-06-06 15:12:00 | Mirati Therapeutics Could Soar Even Higher

2019-06-05 07:30:44 | The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache

2019-06-04 15:18:11 | The 10 Best Stocks for 2019 — So Far

2019-06-04 12:37:00 | Amgen’s Good News on Lung Cancer Boosted Mirati Therapeutics. Here’s What Wall Street Is Saying.

2019-06-04 10:53:28 | How Does Mirati's Lung Cancer Candidate Stack Up Against Amgen's?

2019-06-04 10:19:02 | Amgen's KRAS Inhibitor Shows Impressive Anti-Tumor Activity

2019-06-04 09:21:00 | 3 Cancer Stocks Given a Lift by Amgen

2019-06-03 14:46:06 | Why Cancer-Fighting Stocks & ETFs Are Soaring

2019-06-03 12:47:00 | Amgen Stock Jumps on Promising Cancer Drug Trial Results

2019-06-03 12:18:00 | Here's Why Mirati Therapeutics Is Jumping Today

2019-05-30 16:30:00 | Mirati Therapeutics To Present At Jefferies 2019 Global Healthcare Conference

2019-05-16 16:14:57 | Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting

2019-05-16 14:47:00 | Here's Why Mirati Therapeutics Is Surging Today

2019-05-16 10:47:30 | What's Triggering The Rise In Mirati Shares?

2019-05-14 08:42:12 | Options Traders Expect Huge Moves in Mirati Therapeutics MRTX Stock

2019-05-07 07:10:28 | What You Must Know About Mirati Therapeutics, Inc.'s NASDAQ:MRTX Beta Value

2019-04-29 17:10:37 | Mirati: 1Q Earnings Snapshot

2019-04-29 16:05:00 | Mirati Therapeutics Reports First Quarter 2019 Financial Results

2019-04-29 14:52:19 | Were Hedge Funds Right About Flocking Into Mirati Therapeutics, Inc. MRTX ?

2019-04-01 16:30:00 | Mirati Therapeutics To Present At The H.C. Wainwright & Co. Global Life Sciences Conference

2019-03-26 12:21:32 | The Mirati Therapeutics NASDAQ:MRTX Share Price Has Gained 287%, So Why Not Pay It Some Attention?

2019-03-05 16:30:00 | Mirati Therapeutics To Present At Upcoming Healthcare Conferences

2019-02-28 16:15:00 | Mirati Therapeutics Reports Fourth Quarter Financial Results

2019-02-25 08:10:00 | Analysis: Positioning to Benefit within Biogen, Mirati Therapeutics, PLDT, Zebra Technologies, Domino's Pizza, and Solar Capital — Research Highlights Growth, Revenue, and Consolidated Results

2019-02-19 16:15:00 | Mirati Therapeutics Announces The Appointment Of Faheem Hasnain As Chairman Of The Board Of Directors

2019-02-07 16:30:00 | Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day

2019-02-04 17:01:00 | Here's Why Mirati Therapeutics Jumped 55.8% in January

2019-01-31 07:55:00 | Today's Research Reports on Trending Tickers: bluebird bio and Mirati Therapeutics

2019-01-30 11:41:52 | How Many Insiders Sold Mirati Therapeutics, Inc. NASDAQ:MRTX Shares?

2019-01-23 07:22:47 | The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoporosis Drug Study

2019-01-22 16:01:00 | Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

2019-01-17 08:06:55 | The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US

2019-01-16 20:45:00 | Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock

2019-01-16 16:01:00 | Mirati Therapeutics Announces Proposed Public Offering Of Common Stock

2019-01-15 16:21:00 | Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor

2019-01-15 07:55:00 | Today's Research Reports on Trending Tickers: Aimmune Therapeutics and Mirati Therapeutics

2019-01-10 06:00:00 | Kill the Cancer Stem Cell, Kill the Cancer: How One Biotech is Hitting Cancer at the Cause

2019-01-09 08:39:01 | Mirati Therapeutics MRTX Catches Eye: Stock Jumps 5.4%

2019-01-07 08:30:00 | Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab OPDIVO®

2019-01-02 16:30:00 | Mirati Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference

2018-12-20 16:42:00 | Mirati Therapeutics Added To NASDAQ Biotechnology Index

2018-12-12 03:27:54 | Hedge Funds Are Buying Mirati Therapeutics, Inc. MRTX